[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100433728":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":37,"locations":44,"responsibleParty":91,"collaborators":93,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":99,"sex":105,"minAge":106,"maxAge":10,"enrollmentInfo":107,"targetDuration":10,"studyType":110,"phases":10,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Maastricht Radiation Oncology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"In addition to standard workup and treatment, patients will undergo pre-operatively, after induction of general anaesthesia, an endorectal ultrasound and rigid rectoscopy as study procedures if these are not part of standard workup yet.",[13,14,15],"Diagnostic Test: Ultrasound","Diagnostic Test: Rectoscopy","Other: Scan, e.g. CT (resection specimen)",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"DIAGNOSTIC_TEST","Ultrasound","3D endorectal ultrasound.",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"Rectoscopy","Rigid rectoscopy.",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Scan, e.g. CT (resection specimen)","For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.",[9],[31,35],{"name":32,"affiliation":33,"role":34},"Maaike Berbée, MD, PhD","Maastro","PRINCIPAL_INVESTIGATOR",{"name":36,"affiliation":33,"role":34},"Evert Van Limbergen, MD, PhD",[38,42],{"name":32,"role":39,"phone":40,"phoneExt":10,"email":41},"CONTACT","0031884455600","maaike.berbee@maastro.nl",{"name":36,"role":39,"phone":40,"phoneExt":10,"email":43},"evert.vanlimbergen@maastro.nl",[45,63,74],{"facility":33,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Maastricht","Limburg","6229 ET","Netherlands","NL",{"type":53,"coordinates":54},"Point",[55,56],5.68889,50.84833,{"lat":56,"lon":55},[59,60,61,62],{"name":32,"role":39,"phone":40,"phoneExt":10,"email":10},{"name":36,"role":39,"phone":40,"phoneExt":10,"email":10},{"name":32,"role":34,"phone":10,"phoneExt":10,"email":10},{"name":36,"role":34,"phone":10,"phoneExt":10,"email":10},{"facility":64,"status":46,"city":47,"state":48,"zip":65,"country":50,"countryCode":51,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Maastricht University Medical Center","6229 HX",{"type":53,"coordinates":67},[55,56],{"lat":56,"lon":55},[70,71],{"name":32,"role":39,"phone":40,"phoneExt":10,"email":10},{"name":72,"role":39,"phone":73,"phoneExt":10,"email":10},"Jarno Melenhorst, MD, PhD","0031433874900",{"facility":75,"status":46,"city":76,"state":77,"zip":78,"country":50,"countryCode":51,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Catharina Hospital","Eindhoven","North Brabant","5623 EJ",{"type":53,"coordinates":80},[81,82],5.47778,51.44083,{"lat":82,"lon":81},[85,88],{"name":86,"role":39,"phone":87,"phoneExt":10,"email":10},"An-Sofie Verrijssen, MD","0031402396400",{"name":89,"role":39,"phone":90,"phoneExt":10,"email":10},"Pim Burger, MD, PhD","0031402396600",{"type":92,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[94,95],{"name":64,"class":6},{"name":96,"class":6},"Catharina Ziekenhuis Eindhoven","100433728","detect-target-volume-for-rectal-endoluminal-radiation-boosting-100433728",false,"NCT04927897","DETECT: Target Volume for Rectal Endoluminal Radiation Boosting","DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer","DETECT","Inclusion Criteria:\n\n* ≥18 years of age and capable of giving informed consent.\n* ycT1-3N0(\\*) residual(\\*\\*) histology confirmed rectal adenocarcinoma after neoadjuvant radiotherapy or long-course chemoradiotherapy for which patients will undergo TME surgery.\n* Minimal interval between end of neoadjuvant chemoradiotherapy or radiotherapy: 6 weeks.\n\n(\\*)= as determined by clinical assessment (digital rectal examination, endoscopy with or without biopsy) and\u002For MRI. Biopsy\u002Fhistology around the time of diagnosis is adequate; no biopsy\u002Fhistology is needed after neoadjuvant therapy.\n\n(\\*\\*)= including tumor regrowths\u002Flocal recurrence after an initial clinical complete response and a \"watch and wait\" approach. These patients will also be included after the local recurrence has been determined using endoscopy and\u002For MRI.\n\nExclusion Criteria:\n\n* Patient has received brachytherapy as part of neoadjuvant treatment.\n* \\\u003C18 years of age or incapable of giving informed consent.\n* Patient has not been treated with neoadjuvant radiotherapy or long-course chemoradiotherapy.\n* Patient will not undergo TME surgery for a ycT1-3N0 residual histology confirmed rectal adenocarcinoma.\n* Interval between end of neoadjuvant therapy and surgery is \\\u003C6 weeks.","ALL","18 Years",{"count":108,"type":109},50,"ESTIMATED","OBSERVATIONAL","The aim of the study is to provide prospective data regarding microscopic tumor spread in all directions from the macroscopic tumor in pathology specimens, as seen by eye, and on imaging to define the target volume for endoluminal radiation boosting in rectal cancer patients.",[113],"Rectal Cancer",[113,115,116,117],"Microscopic Tumor Spread","Target Volume Definition","Endoluminal Radiation Boosting","2025-07-24",{"date":120,"type":121},"2025-07-28","ACTUAL",{"date":123,"type":121},"2022-08-16",{"date":125,"type":109},"2027-12",{"name":5,"class":6},3]